Stocktoria
Monopar Therapeutics MNPR
Monopar Therapeutics financials (annual)
Bars are annual figures from 2019 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2025 | FY2025 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | — | — | — | $0 |
| R&D expense | $9.9M | — | — | — | $13.0M | $5.6M | $7.6M | $6.5M | $4.1M | $2.0M |
| Operating income | -$16.7M | — | — | — | -$16.2M | -$8.8M | -$10.5M | -$9.1M | -$6.5M | -$4.3M |
| Income tax | $800 | — | — | — | $800 | $800 | $800 | $0 | $18,361 | $0 |
| Net income | -$13.7M | — | — | — | -$15.6M | -$8.4M | -$10.5M | -$9.1M | -$6.3M | -$4.2M |
| Operating cash flow | -$12.2M | — | — | — | -$6.4M | -$7.9M | -$7.2M | -$7.3M | -$4.7M | -$3.0M |
| Cash & equivalents | $61.8M | $127.7M | $39.5M | $39.7M | $45.8M | $7.3M | $8.2M | $20.3M | $16.7M | $13.2M |
| Total assets | $140.7M | $144.2M | $53.9M | $55.1M | $60.3M | $7.3M | $13.2M | $20.5M | $16.9M | $13.4M |
| Total liabilities | $2.9M | $2.6M | $1.7M | $1.5M | $5.3M | $1.8M | $3.1M | $1.6M | $1.2M | $724,165 |
| Shareholders' equity | $137.8M | $141.6M | $52.2M | $53.6M | $55.0M | $5.6M | $10.1M | $18.9M | $15.7M | $12.6M |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.